Sacral neuromodulation, which is also called interstim, acts to provide a small amount of electrical stimulation to the nerves that run through the tailbone (sacrum) to the bladder. For reasons we do ...

InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...

NASHVILLE, Tenn. (Ivanhoe Newswire) – It’s a taboo topic that nobody talks about but, almost one in six Americans suffer with urinary or bowel incontinence. That’s more than the number of people with ...

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...

One of the world's largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...

InterStim therapy is an implanted stopwatch-sized device that acts as a 'pacemaker' by determining the rate of firing of the muscles in the pelvic floor and can change the way the bladder and bowel ...

(RTTNews) - Medtronic plc. (MDT) said Monday that it has filed a pre-market approval or PMA supplement with the United States Food and Drug Administration or FDA for approval of its InterStim Micro ...

(WNDU) - It’s a taboo topic that nobody talks about. But 1 in 6 Americans suffer with either urinary or bowel incontinence. That’s more than the number of people with Alzheimer’s, diabetes, or breast ...

After receiving an FDA approval earlier this week for its newly miniaturized and rechargeable sacral nerve stimulator, Medtronic reported that its first patient has received the implant through the ...

Medtronic plc has won U.S. FDA approval of its Interstim Micro rechargeable sacral nerve stimulator and Interstim Surescan MRI leads for the treatment of urinary and bowel dysfunctions. The new ...

POMPANO BEACH, Fla.--(BUSINESS WIRE)--StimGuard, a privately-held, pre-commercial medical device company, today announced it is commencing a head-to-head study for its Chronic Affarent Nerve ...